Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

1.

[Tunisian experience in the treatment of aggressive non Hodgkin's lymphoma in adults: about 337 patients].

Laatiri MA, Elloumi M, Ali ZB, Ben Othmen T, Msadek F, Toumi N, Bouaouina N, Daoud J, Maalej M, Ghannem H, Meddeb B.

Bull Cancer. 2010 Apr;97(4):409-16. doi: 10.1684/bdc.2010.1084. French.

PMID:
20374978
[PubMed - indexed for MEDLINE]
2.

Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.

Intragumtornchai T, Bunworasate U, Nakorn TN, Rojnuckarin P.

Leuk Lymphoma. 2006 Jul;47(7):1306-14.

PMID:
16923561
[PubMed - indexed for MEDLINE]
3.

Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.

Stewart DA, Bahlis N, Valentine K, Balogh A, Savoie L, Morris DG, Jones A, Brown C, Russell JA.

Blood. 2006 Jun 15;107(12):4623-7. Epub 2006 Feb 7.

PMID:
16467197
[PubMed - indexed for MEDLINE]
Free Article
4.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
[PubMed - indexed for MEDLINE]
5.

Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.

van Imhoff GW, van der Holt B, Mackenzie MA, Van't Veer MB, Wijermans PW, Ossenkoppele GJ, Schouten HC, Sonneveld P, Steijaert MM, Kluin PM, Kluin-Nelemans HC, Verdonck LF; Dutch-Belgian Hemato-Oncology Cooperative Group.

J Clin Oncol. 2005 Jun 1;23(16):3793-801. Epub 2005 Apr 4.

PMID:
15809447
[PubMed - indexed for MEDLINE]
Free Article
6.

Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.

Federico M, Clò V, Brugiatelli M, Carotenuto M, Gobbi PG, Vallisa D, Lombardo M, Avanzini P, Di Renzo N, Dini D, Baldini L, Silingardi V.

Haematologica. 1998 Sep;83(9):800-11.

PMID:
9825577
[PubMed - indexed for MEDLINE]
Free Article
7.

Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.

Gordon LI, Andersen J, Colgan J, Glick J, Resnick GD, O'Connell M, Cassileth PA.

Cancer. 1995 Feb 1;75(3):865-73.

PMID:
7530168
[PubMed - indexed for MEDLINE]
8.

Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, Bittner S, Schmalenberg H, Schmits R, Pfreundschuh M, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Ann Oncol. 2003 Jun;14(6):881-93.

PMID:
12796026
[PubMed - indexed for MEDLINE]
Free Article
9.

[Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].

Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.

Ai Zheng. 2006 Apr;25(4):486-9. Chinese.

PMID:
16613686
[PubMed - indexed for MEDLINE]
10.

A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.

Lambertenghi Deliliers G, Butti C, Baldini L, Ceriani A, Lombardi F, Luoni M, Montalbetti L, Pavia G, Pinotti G, Pogliani E, et al.

Haematologica. 1995 Jul-Aug;80(4):318-24.

PMID:
7590500
[PubMed - indexed for MEDLINE]
Free Article
11.

CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.

De Lena M, Ditonno P, Lorusso V, Brandi M, Timurian A, Marzullo F, Ventrella V, Pellecchia A.

J Clin Oncol. 1995 Apr;13(4):953-60.

PMID:
7535844
[PubMed - indexed for MEDLINE]
12.

A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remission.

Stahel RA, Jost LM, Kroner T, Dommann-Scherrer C, Maurer R, Glanzmann C, Jacky E, Pichert G, Pestalozzi B, Marincek B, Sauter C, Honegger H.

Br J Haematol. 1999 Mar;104(4):763-9.

PMID:
10192438
[PubMed - indexed for MEDLINE]
13.

Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte.

Blood. 2003 Dec 15;102(13):4284-9. Epub 2003 Aug 14.

PMID:
12920037
[PubMed - indexed for MEDLINE]
Free Article
14.

A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results.

Khaled HM, Zekri ZK, Mokhtar N, Ali NM, Darwish T, Elattar I, Gaafar R, Moawad MS.

Ann Oncol. 1999 Dec;10(12):1489-92.

PMID:
10643541
[PubMed - indexed for MEDLINE]
Free Article
15.

Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.

Biswas T, Dhakal S, Chen R, Hyrien O, Bernstein S, Friedberg JW, Fisher RI, Liesveld J, Phillips G, Constine LS.

Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):79-85. doi: 10.1016/j.ijrobp.2009.04.036. Epub 2009 Aug 3.

PMID:
19647953
[PubMed - indexed for MEDLINE]
16.

VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.

Santini G, Coser P, Congiu AM, Salvagno L, De Souza C, Sertoli MR, Olivieri A, Chisesi T, Rubagotti A, Truini M, Contu A, Porcellini A, Zambaldi G, Nati S, Marino G, Rizzoli V.

Haematologica. 2000 Feb;85(2):160-6.

PMID:
10681723
[PubMed - indexed for MEDLINE]
Free Article
17.
18.

VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.

Santini G, Salvagno L, Leoni P, Chisesi T, De Souza C, Sertoli MR, Rubagotti A, Congiu AM, Centurioni R, Olivieri A, Tedeschi L, Vespignani M, Nati S, Soracco M, Porcellini A, Contu A, Guarnaccia C, Pescosta N, Majolino I, Spriano M, Vimercati R, Rossi E, Zambaldi G, Mangoni L, Rizzoli V, et al.

J Clin Oncol. 1998 Aug;16(8):2796-802.

PMID:
9704732
[PubMed - indexed for MEDLINE]
19.

Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.

Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, Billaud E, Raphael M, Lancar R, Costagliola D.

J Clin Oncol. 2006 Sep 1;24(25):4123-8. Epub 2006 Aug 8.

PMID:
16896005
[PubMed - indexed for MEDLINE]
Free Article
20.

A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma.

Linch DC, Smith P, Hancock BW, Hoskin PJ, Cunningham DC, Newland AC, Milligan D, Stevenson PA, Wood JK, Maclennan KA, Vaughan B, Vaughan G, Gregory WM.

Ann Oncol. 2000;11 Suppl 1:87-90.

PMID:
10707786
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk